African Regional IP Organization (ARIPO): These 4 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,204
Patent Title: 4-phenylamino-quinazolin-6-yl-amides.

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-three patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: nebivolol hydrochloride; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 04, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,815
Patent Title: Compositions comprising nebivolol

BYVALSON is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries. There has been litigation on patents covering BYVALSON

See drug price trends for BYVALSON.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

Generic name: nebivolol hydrochloride; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 04, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,896
Patent Title: Compositions comprising nebivolol

BYVALSON is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries. There has been litigation on patents covering BYVALSON

See drug price trends for BYVALSON.

The generic ingredient in BYVALSON is nebivolol hydrochloride; valsartan. There are fourteen drug master file entries for this API. Additional details are available on the nebivolol hydrochloride; valsartan profile page.

Generic name: ivabradine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 1,956
Patent Title: y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

Generic name: ivabradine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 1,907
Patent Title: Beta-crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical compositions containing it

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.